Psoriatic Arthritis | DecisionBase | US/EU5 | 2014
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors
The availability of tumor necrosis factor alpha (TNF-α) inhibitors as therapeutic options has revolutionized the treatment of psoriatic arthritis (PsA). The TNF-α inhibitors have set a high clinical standard (e.g., excellent efficacy in both peripheral and axial PsA, low risk of organ toxicity) that is challenging for emerging therapies to surpass. However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. A number of therapies, including those that will offer improvements over the TNF-α inhibitors on delivery or safety, are in late-stage development for PsA; however, based on the current trial data for these agents, significant opportunity remains for new drugs that offer efficacy that surpasses that of the TNF-α inhibitors.
